This flexibility of tumor cells, together with the heterogeneity of EGFR expression in general [121], the strong crosstalk and association of the receptor with multiple pathways and invasion- and angiogenic-regulating proteins, and the ability to develop resistance mechanisms are the reasons why mono-therapy of EGFR therapeutics have so far only been partially successful. This evidence concerns the gene EGFR and neoplasm.